Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

• Published in: European journal of cancer (1990) 2024-03, Vol.200, p.113601-113601, Article 113601
• Main Authors: Egeler, Mees, Lai-Kwon, Julia, Tissier, Renaud, Fraterman, Itske, Kuijpers, Anke, Van Houdt, Winan, Wilgenhof, Sofie, Rao, Aparna, Sandhu, Shahneen, Lee, Rebecca, Eriksson, Hanna, van Leeuwen, Marieke, de Ligt, Kelly, van Akkooi, Alexander, van de Poll-Franse, Lonneke
• Format: Article
• Language: English
• Subjects: Adjuvant anti-PD1 therapy; Adjuvants, Immunologic; Combined Modality Therapy; Health-related quality of life (HRQOL); Humans; Medicin och hälsovetenskap; Melanoma - drug therapy; Melanoma - surgery; Quality of Life; Resected stage III/IV melanoma; Skin Neoplasms - drug therapy; Skin Neoplasms - surgery
• ISSN: 0959-8049; 1879-0852; 1879-0852
• DOI: 10.1016/j.ejca.2024.113601

While adjuvant therapy with anti-programmed cell death protein-1 (anti-PD1) for patients with resected stage III/IV melanoma has been shown to improve recurrence-free survival, the overall survival benefit remains uncertain. This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma Data was used from two melanoma registries in Australia and the Netherlands. Patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 who completed a baseline and at least one post-baseline HRQOL assessment were included. HRQOL was assessed using the EORTC QLQ-C30 at baseline, 3, 6, and 12 months. Established thresholds were used for interpreting changes in QLQ-C30 scores. 92 patients were included. Mean symptom and functioning scores improved or remained stable at 12 months compared to baseline. However, a substantial proportion of patients experienced a clinically significant decline in role (39%, μ = −50.8), social (41%, μ = −32.7), or emotional (50%, μ = −25.1) functioning at 12 months compared to baseline. Younger patients were more likely to experience clinically significant deteriorations in role (OR=1.07, 95% CI: 1.02–1.13, p